Perfluorinated HDAC inhibitors as selective anticancer agents

Org Biomol Chem. 2017 Nov 7;15(43):9186-9190. doi: 10.1039/c7ob02339a.

Abstract

A series of potent histone deacetylase inhibitors is presented that incorporate alkyl or perfluorinated alkyl chains. Several new compounds show greater in vitro antiproliferative activity than the clinically approved inhibitor, SAHA. Furthermore, the new compounds show up to 5-fold greater activity against cancer cells than healthy cells. This selectivity is in contrast to SAHA, which is more active against the healthy cell line than the cancer cell line tested. Finally, we report an increase in activity for SAHA under mild hyperthermia, indicating that it could be an interesting candidate to use in combination with thermal therapy.

MeSH terms

  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / pharmacology*
  • Cell Line, Tumor
  • Halogenation*
  • Histone Deacetylase Inhibitors / chemistry*
  • Histone Deacetylase Inhibitors / pharmacology*
  • Histone Deacetylases / chemistry
  • Histone Deacetylases / metabolism
  • Humans
  • Models, Molecular
  • Protein Conformation
  • Repressor Proteins / chemistry
  • Repressor Proteins / metabolism

Substances

  • Antineoplastic Agents
  • Histone Deacetylase Inhibitors
  • Repressor Proteins
  • HDAC8 protein, human
  • Histone Deacetylases